Sihuan Pharmaceutical Expects H1 Profit to Soar At Least 217%
MT Newswires Live
Jul 27
Sihuan Pharmaceutical Holdings Group (HKG:0460) expects to report net profit of at least 210 million yuan for the first half of 2026, up at least 217% from a year earlier.
Revenue is expected to be at least 1.14 billion yuan, roughly unchanged from a year earlier, according to a Tuesday Hong Kong bourse filing.
The company attributed the expected profit growth to steady development of its medical aesthetics business, continued commercialization of its innovative drug portfolio, and a significant increase in its share of profit from an associate.
Shares of the pharmaceutical company rose over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.